Ultra-sensitive and selective fluorescence approach for estimation of elagolix in real human plasma and content uniformity using boron-doped carbon quantum dots

Elagolix (ELX) is an orally administered non-peptidic GnRH antagonist that has been approved by the Food and Drug Administration in 2018 for the treatment of endometriosis pain. A sensitive and selective method for estimating elagolix (ELX) in human plasma and content uniformity was developed and va...

Descripción completa

Detalles Bibliográficos
Autores principales: Salman, Baher I., Hassan, Ahmed I., Hassan, Yasser F., Saraya, Roshdy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351230/
https://www.ncbi.nlm.nih.gov/pubmed/35922841
http://dx.doi.org/10.1186/s13065-022-00849-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351230/
https://www.ncbi.nlm.nih.gov/pubmed/35922841
http://dx.doi.org/10.1186/s13065-022-00849-3

Ejemplares similares